Registry update — unassessed
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 22, 2026 · Discovered: Sep 23, 2026 · Assessed: — · Research update
What it does not prove
- The abstract describes a protocol or planned study, not results—no actual effects on morbidity or mortality are reported
- Sample size, duration, primary outcomes, and effect estimates are not provided, so the magnitude or statistical significance of any effect cannot be assessed
- This appears to be a trial protocol rather than a completed study report
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Adults living with obesity
- Primary outcome
- Reduction of morbidity and mortality in adults with obesity
- Effect size
- —
- Significance
- Not reported
- Journal
- Eli Lilly and Company
- Published
- Sep 22, 2026
Sources
Primary source
- Eli Lilly and Company ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.